Gold prices slip after rallying on Powell rate cut talk
MORRISVILLE, NC—Jason Adair, the Chief Business Officer of Liquidia Corp (NASDAQ:LQDA), a $1.21 billion market cap company, recently sold a portion of his holdings in the company. According to InvestingPro data, the stock is currently trading in overbought territory, with shares showing strong momentum over recent months. According to a filing with the Securities and Exchange Commission, Adair sold 445 shares of Liquidia common stock on January 27, 2025, at a price of $14.20 per share, totaling approximately $6,319. With analyst price targets ranging from $17 to $31, this transaction comes at an interesting time for the stock.
The shares were sold to cover taxes associated with the settlement of restricted stock units (RSUs) initially granted to Adair on July 6, 2023. This transaction was executed under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling stocks.
Following this transaction, Adair holds 179,770 shares directly, which include various unvested RSUs and shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. For deeper insights into insider transactions and comprehensive analysis, including 10+ additional ProTips, check out the full company report on InvestingPro.
In other recent news, Liquidia Corporation announced robust Q3 results, with revenue rising to $4.4 million from $3.7 million in the same quarter last year. Despite a net loss of $23.2 million, the company maintains a solid cash position of $204.4 million. These developments come as Liquidia gears up for the anticipated 2025 launch of their inhaled treatment YUTREPIA, post the expiration of TYVASO DPI’s exclusivity.
The company is also working on the development of a next-generation nebulizer and preparing for the pivotal study of their product L606, set to begin in the first half of 2025. An expanded partnership with Pharmosa is aiding in the development of this next-generation nebulizer.
These recent developments highlight Liquidia’s focus on innovation and commitment to addressing the needs of patients with pulmonary hypertension. As the company continues to progress, further updates are expected.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.